Patient Perspectives on Novel Treatments in Haemophilia: A Qualitative Study-Reference-Cited by-同舟云学术

Patient Perspectives on Novel Treatments in Haemophilia: A Qualitative Study

Published:2019-11-06 Issue:2 Volume:13 Page:201-210
ISSN:1178-1653
Container-title:The Patient - Patient-Centered Outcomes Research
language:en
Short-container-title:Patient

Author:

van Balen Erna C.^ORCID,Wesselo Marjolein L.,Baker Bridget L.,Westerman Marjan J.^ORCID,Coppens Michiel,Smit Cees,Driessens Mariëtte H. E.,Leebeek Frank W. G.,van der Bom Johanna G.^ORCID,Gouw Samantha C.^ORCID

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1007/s40271-019-00395-6.pdf

Reference26 articles.

1. Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–47. https://doi.org/10.1111/j.1365-2516.2012.02909.x .

2. Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935–9. https://doi.org/10.1111/jth.12672 .

3. Hoyer LW, Hemophilia A. N Engl J Med. 1994;330(1):38–47.

4. Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis. 2012;7:24.

5. Plug I, Van Der Bom JG, Peters M, Mauser-Bunschoten EP, De Goede-Bolder A, Heijnen L, et al. Mortality and causes of death in patients with hemophilia, 1992–2001: a prospective cohort study. J Thromb Haemost. 2006;4(3):510–6. https://doi.org/10.1111/j.1538-7836.2006.01808.x .

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Blood biodistribution and vector shedding of valoctocogene roxaparvovec in people with severe hemophilia A;Blood Advances;2024-08-30

2. Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A;Molecular Therapy;2024-07

3. Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A;Journal of Thrombosis and Haemostasis;2024-07

4. Long‐term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post‐treatment;Haemophilia;2024-02-05

5. Perspectives and perception of haemophilia gene therapy by French patients;Haemophilia;2023-12-06